Our documents

Monitoring tool for rare diseases (2025)

Update of our monitoring tool on new therapies with an indication in a rare condition and on cell and gene therapies. In collaboration with Synergyx Conseils Inc. and KMPG. This...

Quebec’s Life Sciences Venture Capital Landscape

To ensure that startups in Quebec’s life sciences and health technologies (LSHT) sector have access to funding throughout their growth journey, Montréal InVivo took the initi...

Montréal InVivo’s Activity Report 2023

Montreal InVivo’s Digital Propulsion Grant

The “Digital Propulsion” grant offered by Montréal InVivo provides selected companies with personalized support from an expert consultant. Take advantage of essenti...

Intercluster Action Plan in Sustainable Development

Scientific watch for new therapies indicated in the treatment of rare conditions as well as cell and gene technologies

Presentation of our Scientific watch for new therapies indicated in the treatment of rare conditions as well as cell and gene technologies.   Produced by Synergyx Conseils ...

Montréal InVivo’s Activity Report 2022

Law 25 – What to expect

Law 25 will gradually come into force over the next three years, starting on September 22, 2022. In the attached document, you will find the measures required by the law and the...